Skip header and navigation

25 records – page 1 of 3.

Document Type
Rapid Review
Review Code
EOC062201v2 RR
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC062201v2 RR
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
Updated Key Findings
Generally speaking, data indicate that adult cancer patients and those who have recently received or are receiving anti-cancer therapy are at a higher risk of severe outcomes and death resulting from COVID-19 compared to those without cancer. However, more data are beginning to elucidate the nuances of these risks depending on patient specific factors.
Limited data indicate that pediatric cancer patients are not at a high level of risk of severe outcomes from COVID-19.
Limited evidence indicates some differences in the course and severity of SARS-CoV-2 infection depending on the type of immunosuppressive therapy a patient receives.
Key Findings
Generally speaking, data indicate that adult cancer patients and those who have recently received or are receiving anti-cancer therapy are at a higher risk of severe outcomes and death resulting from COVID-19 compared to those without cancer.
Pediatric cancer populations may not be at the same level of risk as adult populations.
There is not enough evidence at this time to determine if there are differences in the course of SARS-CoV-2 infection in patients receiving chemotherapy vs. those who are not aside from outcomes and severity.
Category
Clinical Presentation
Subject
Chemotherapy
Cancer
Comorbidities
Natural History
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Vanstone, J; Groot, G; Miller, L; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 22; Document no.: EOC062201v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Review History
EOC062201 RR: June 29, 2020
Related Documents
Documents
Less detail
Document Type
Table
Review Code
EOC062201v2 RR Table
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
Document Type
Table
Review Code
EOC062201v2 RR Table
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
Category
Clinical Presentation
Subject
Chemotherapy
Cancer
Comorbidities
Natural History
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Vanstone, J; Groot, G; Miller, L; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 22; Document no.: EOC062201v2 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST table)
Review History
EOC062201 RR: June 29, 2020
Related Documents
Documents

EOC062201v2 RR Table

Download File
Less detail
Document Type
Evidence Search Report
Review Code
EOC062201v2-01 ESR
Question Submitted
June 22, 2020
Date Completed
January 4, 2021
Status
5. Updated review
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC062201v2-01 ESR
Question Submitted
June 22, 2020
Date Completed
January 4, 2021
Status
5. Updated review
Research Team
EOC
Category
Clinical Presentation
Subject
Comorbidities
Chemotherapy
Cancer
Natural History
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Miller, L.; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 4; Document no.: EOC062201v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 46 p. (CEST evidence search report)
Review History
EOC062201 RR: June 29, 2020
Related Documents
Documents

EOC062201v2-01 ESR

Read PDF Download PDF
Less detail
Document Type
Rapid Review
Review Code
EOC091601 RR
Question Submitted
September 16, 2020
Date Completed
October 13, 2020
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC091601 RR
Question Submitted
September 16, 2020
Date Completed
October 13, 2020
Status
3. Completed
Research Team
EOC
Key Findings
· There is no consistent definition of the post-acute COVID syndrome. · There is a need to distinguish between the rehabilitation needs of severe COVID patients and the persistent collection of symptoms that occur for a variable period of time in some patients. · Individuals with severe initial infections are more likely to have ongoing symptoms · The duration of post-covid symptoms is unclear at this point in time · The common post-covid symptoms can be grouped as general, respiratory, cardiovascular, mental health, and neurologic sequelae. · A follow up review is probably warranted
Category
Healthcare Services
Clinical Presentation
Subject
Long Covid
Natural History
Treatment
Priority Level
Level 5 completed within 2 weeks
Cite As
Badea, A; Groot, G; Dalidowicz, M; Fox, L. What is the post acute covid syndrome and its implications in terms of health services? 2020 Oct 13; Document no.: EOC091601 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 28 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC091601-01 ESR
Question Submitted
September 16, 2020
Date Completed
September 18, 2020
Status
3. Completed
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC091601-01 ESR
Question Submitted
September 16, 2020
Date Completed
September 18, 2020
Status
3. Completed
Research Team
EOC
Category
Healthcare Services
Clinical Presentation
Subject
Long Covid
Natural History
Treatment
Priority Level
Level 5 completed within 2 weeks
Cite As
Dalidowicz, M; Fox, L. What is the post acute covid syndrome and its implications in terms of health services? 2020 Sep 18; Document no.: EOC091601-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 40 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC070201v2 RR
Question Submitted
July 2, 2020
Date Completed
August 14, 2020
Status
5. Updated review
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC070201v2 RR
Question Submitted
July 2, 2020
Date Completed
August 14, 2020
Status
5. Updated review
Research Team
EOC
Updated Key Findings
AUGUST 7th UPDATE: No new studies examining secondary attack rates of pediatric index cases were found. Studies continue to suggest low transmission from pediatric cases, and high proportion of pediatric cases being asymptomatic to mildly symptomatic.
Key Findings
· Pediatric cases of COVID-19 constitute between 1% to 10% of all confirmed cases of COVID-19; variation exists by jurisdiction. · Few case reports exist of confirmed child-to-other transmission. Contact tracing studies suggest that children are unlikely to be transmitters of the disease. Households are the most likely environments for transmission. · A recent large South Korean contact tracing study however (in pre-print) found that household COVID-19 transmission rates for children age 10-19 were significantly higher than in adults; transmission rates for children age 0-9 were relatively low.
Category
Infection Prevention and Control
Epidemiology
Subject
Pediatrics
Transmission
Symptoms
Natural History
Priority Level
Level 5 completed within 2 weeks
Cite As
Sulaiman, F; Groot, G; Muhajarine, N; Dalidowicz, M; Miller, L. What is the transmissibility and epidemiology of COVID-19 in children and adolescents? 2020 Aug 14; Document no.: EOC070201v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 12 p. (CEST rapid review report)
Review History
EOC070201 RR: July 22, 2020
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC070201v2-01 ESR
Question Submitted
July 2, 2020
Date Completed
August 7, 2020
Status
5. Updated review
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC070201v2-01 ESR
Question Submitted
July 2, 2020
Date Completed
August 7, 2020
Status
5. Updated review
Research Team
EOC
Category
Infection Prevention and Control
Epidemiology
Subject
Pediatrics
Transmission
Symptoms
Natural History
Priority Level
Level 5 completed within 2 weeks
Cite As
Dalidowicz, M; Ellsworth, C. What is the transmissibility and epidemiology of COVID-19 in children and adolescents? 2020 Aug 7; Document no.: EOC070201v2-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 29 p. (CEST evidence search report)
Review History
EOC070201 RR: July 22, 2020
Related Documents
Documents

EOC070201v2-01 ESR

Read PDF Download PDF
Less detail
Document Type
Evidence Search Report
Review Code
EOC072102-01 ESR
Question Submitted
July 27, 2020
Date Completed
July 31, 2020
Status
3. Completed
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC072102-01 ESR
Question Submitted
July 27, 2020
Date Completed
July 31, 2020
Status
3. Completed
Research Team
EOC
Category
Epidemiology
Subject
Pediatrics
Natural History
Symptoms
Transmission
Population
All Pediatrics
Priority Level
Level 5 completed within 2 weeks
Cite As
Dalidowicz, M; Howell-Spooner, B; Ellsworth, C. What is the disease progression and epidemiology of COVID-19 in pediatric populations? 2020 Jul 31; Document no.: EOC072102-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 44 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC072102 RR
Question Submitted
July 27, 2020
Date Completed
July 31, 2020
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC072102 RR
Question Submitted
July 27, 2020
Date Completed
July 31, 2020
Status
3. Completed
Research Team
EOC
Key Findings
· Children and adolescents (0 to 18 years) contributed 1- 10% of laboratory confirmed cases of COVID-19 globally. · Children have been reported to have milder symptoms of COVID-19 and have shown better prognosis as compared to adults. · Severe cases presenting as a multisystem inflammatory syndrome in children (MIS-C) has been reported in some pediatric cases of COVID-19. Many of these children meet the criteria for complete or incomplete Kawasaki disease, but different clinical presentations of this inflammatory disorder are being reported. · Underlying medical conditions and comorbidities such as such as sickle cell disease, immunocompromised condition, obesity, cancer, cardiovascular disease, and asthma have been associated with severity and complications from COVID-19 infection in pediatric patients. · Although rare, death from COVID-19 in children have been reported, with a case fatality rate of less than 0.5%.
Category
Epidemiology
Subject
Pediatrics
Natural History
Symptoms
Transmission
Population
All Pediatrics
Priority Level
Level 5 completed within 2 weeks
Cite As
Asamoah, G; Muhajarine, N; Dalidowicz, M; Ellsworth, C; Howell-Spooner, B. What is the disease progression and epidemiology of COVID-19 in pediatric populations? 2020 Jul 27; Document no.: EOC072102 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 17 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EPM051301 RR
Question Submitted
May 13, 2020
Date Completed
June 3, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
Document Type
Rapid Review
Review Code
EPM051301 RR
Question Submitted
May 13, 2020
Date Completed
June 3, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
Key Findings
· There is marked heterogeneity across studies in reported estimates of the proportion of asymptomatic SARS CoV-2 infections that range from 1% to 80%. · The proportion of SARS CoV-2 infections that are asymptomatic is related to the method of estimation, the population studied, setting and the timing of the estimation during the epidemic.
Category
Clinical Presentation
Epidemiology
Subject
Symptoms
Asymptomatic
Transmission
Natural History
Priority Level
Level 4 completed within 1 week
Cite As
Williams-Roberts, H; Basran, J; Dalidowicz, M; Young, C; Mueller, M. What proportion of disease transmission is due to persons who are asymptomatic over the entire course of illness? 2020 Jun 2; Document no.: EPM051301 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 33 p. (CEST rapid review report)
Similar Reviews
LAB040701 RR
LAB040701v2 RR
Related Documents
Documents
Less detail

25 records – page 1 of 3.